Does bosutinib treat ALS?

Bosutinib (Bosutinib) is a tyrosine kinase inhibitor mainly used to treat chronic myeloid leukemia (CML) . Currently, there is insufficient evidence that bosutinib is effective in treating ALS (Amyotrophic Lateral Sclerosis). ALS is a degenerative disease of the nervous system, also known as amyotrophic lateral sclerosis. There is currently no specific drug that can cure or prevent its progression.

ALS is characterized by the progressive degeneration of nerve cells in the spinal cord and brain. The treatment of ALS requires comprehensive treatment under the guidance of a doctor, including drug treatment, rehabilitation training, psychological support, etc. Bosutinib is a TKI. Bosutinibmainly inhibitsBCR-ABL kinase that promotes chronic myelogenous leukemia; it is also an inhibitor of Src family kinases including Src, Lyn and Hck. Bosutinib inhibits 16 of 18 imatinib-resistant forms of BCR-ABL kinase expressed in murine myeloid cell lines. Bosutinib does not inhibit T315I and V299L mutant cells.

The originator drug of bosutinib is not marketed in the country, so it cannot be included in medical insurance. Currently, the original drugs sold overseas include Turkish version and European version. The price of the Turkish version may be more than RMB 2,000 per box of 500mg*28, and the price of the European version may be more than RMB 30,000 (the price may fluctuate due to the exchange rate). There are also bosutinib generic drugs produced overseas in other countries. Their pharmaceutical ingredients are basically the same as those of the original drug. The price of 500mg*30 per box may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.